{
  "name": "TXP_ELIGIBILITY",
  "description": "Transplant eligibility requirements met.",
  "primaryKey": [
    {
      "columnName": "PAT_ENC_CSN_ID",
      "ordinalPosition": 1
    },
    {
      "columnName": "LINE",
      "ordinalPosition": 2
    }
  ],
  "columns": [
    {
      "ordinalPosition": 1,
      "name": "PAT_ENC_CSN_ID",
      "type": "NUMERIC",
      "discontinued": false,
      "description": "The unique contact serial number for this contact. This number is unique across all patient encounters in your system. If you use IntraConnect, this is the Unique Contact Identifier (UCI)."
    },
    {
      "ordinalPosition": 2,
      "name": "LINE",
      "type": "INTEGER",
      "discontinued": false,
      "description": "The line number for the information associated with this contact. Multiple pieces of information can be associated with this contact."
    },
    {
      "ordinalPosition": 3,
      "name": "PAT_ENC_DATE_REAL",
      "type": "FLOAT",
      "discontinued": false,
      "description": "A unique contact date in decimal format. The integer portion of the number indicates the date of contact. The digits after the decimal distinguish different contacts on the same date and are unique for each contact on that date. For example, .00 is the first/only contact, .01 is the second contact, etc."
    },
    {
      "ordinalPosition": 4,
      "name": "CONTACT_DATE",
      "type": "DATETIME",
      "discontinued": false,
      "description": "The date of this contact in calendar format."
    },
    {
      "ordinalPosition": 5,
      "name": "CM_CT_OWNER_ID",
      "type": "VARCHAR",
      "discontinued": false,
      "description": "The Community ID (CID) of the instance that owns this contact. This is only populated if you use IntraConnect."
    },
    {
      "ordinalPosition": 6,
      "name": "TXP_ELIGIBILITY_C_NAME",
      "type": "VARCHAR",
      "discontinued": false,
      "description": "Transplant waitlist eligibility criteria for committee review.",
      "entries": [
        "Cystic fibrosis",
        "Suitable medical and psychosocial evaluation",
        "Legal resident of the US",
        "Life expectancy without transplant < life expectancy with transplant",
        "Demonstration of the ability to comply with the post-transplant regimen",
        "Congenital heart disease not amenable to repair",
        "Failure of standard medical-surgical therapy to reverse the cardiac failure",
        "Intractable ventricular and dysrhythmias",
        "NYHA heart failure class 3 or 4",
        "Progressively worsening heart failure",
        "Unresectable cardiac tumor",
        "V02 < 12",
        "Alpha 1-antitrypsin deficiency",
        "Acquired obstructive nephropathy",
        "Acute and subacute glomerulonephritis",
        "Acute tubular necrosis (ATN)",
        "Amyloidosis",
        "Analgesic nephropathy",
        "Anaphylactoid purpura (Henoch-Schonlein)",
        "Aplasia or hypoplasia",
        "Chronic glomerulonephritis",
        "Chronic pyelonephritis",
        "Congenital obstructive nephropathy",
        "Cortical necrosis",
        "Creatinine clearance < 20cc per minute or uremic symptoms",
        "Cystinosis",
        "Diabetic nephropathy",
        "Doumented chronic renal failure of at least 6-8 weeks duration with etiology unknown",
        "End-stage renal disease",
        "Goodpasture's disease (anti-glomerular base-membrane disease)",
        "Gout nephritis",
        "Hemolytic uremic syndrome",
        "Hereditary Nnephropathies (Alport's syndrome)",
        "HIV-associated nephropathy",
        "Horseshoe kidney",
        "Hyperoxaluria or oxalosis",
        "Hypertensive nephrosclerosis",
        "Hypocomplementemic nephritis",
        "If HIV positive, CD4 > or = 200 and clinical clearance",
        "Irreversible acute renal failure",
        "Irreversible chronic renal failure",
        "Irreversible renal failure defined as GFR < 20cc/minute/1.73m2",
        "Lead nephropathy",
        "Lupus erythematosus (SLE)",
        "Macroglobulinemia",
        "Medullary cystic disease",
        "Multiple myeloma",
        "Nephrocalcinosis",
        "Pediatrics only - weight > or = 10 kg and length > or = 80 cm",
        "Polyarteritis (periarterititis nodosa)",
        "Polycystic kidney disease",
        "Renal artery occlusion",
        "Renal vein thrombosis",
        "Scleroderma",
        "Toxic nephropathies",
        "Trauma requiring nephrectomy",
        "Tuberous sclerosis",
        "Tumors requiring nephrectomy renal carcinoma",
        "Wegener's granulomatosis",
        "Wilms' tumor",
        "Acute fulminant hepatic failure",
        "Adenomatosis",
        "Alagille syndrome",
        "Alcoholic cirrhosis",
        "Ascites",
        "Autoimmune chronic active hepatitis (CAH)",
        "Autoimmune hepatitis",
        "Biliary atresia",
        "Caroli's disease",
        "Cholangiocarcinoma",
        "Cholestatic liver disease",
        "Chronic Hepatitis B",
        "Chronic Hepatitis C",
        "Decreased albumin",
        "Decreased platelets < 120K",
        "Defects in bilirubin conjugation",
        "Diminishing quality of life",
        "Drug-induced CAH",
        "Encephalopathy",
        "Failed allograft",
        "Fulminant hepatic failure",
        "Glycogen storage disease",
        "Hepatitis B (under special antiviral/antibody protocols)",
        "Hepatic tumors: Hepatoblastoma",
        "Hepatic tumors: Hepatocellular carcinoma",
        "Hepatitis C",
        "Hepatitis: Autoimmune",
        "Hepatitis: Pharmacologic injury",
        "Hepatitis: Viral",
        "Hepatoma",
        "Hepatorenal syndrome",
        "HIV",
        "Idiopathic or cryptogenic CAH or cirrhosis",
        "Increased bilirubin",
        "Increased prothrombin time",
        "Inherited liver diseases",
        "Laennec's cirrhosis",
        "Liver cancer, hepatocellular carcinoma",
        "Liver disease from external agents",
        "Liver failure due to toxins",
        "Maple syrup urine disease",
        "Marked prolongation of prothrombin time",
        "Maximal medical/surgical therapy has been exhausted and is no longer effective",
        "Metabolic liver disease: Ornithine transcarbarmylase deficiency",
        "Metabolic liver disease: Tyrosinemia",
        "Neonatal hepatitis",
        "Neuroendocrine tumors",
        "Non-alcoholic steato-hepatitis (NASH)",
        "Other undefined etiologies",
        "Pediatric hepatoblastoma",
        "PELD score > or = 7",
        "Polycystic disease",
        "Post-necrotic (including viral) cirrhosis",
        "Primary hepatocellular carcinoma if no viable tumor, status post-treatment",
        "Primary hepatocellular carcinoma if tumor meets size criteria",
        "Primary hepatocellular carcinoma if no macrovascular involvement",
        "Primary hepatocellular carcinoma if no identifiable extrahepatic spread of tumor",
        "Primary hepatocellular carcinoma if not a candidate for subtotal liver resection",
        "Primary biliary cirrhosis",
        "Primary hemochromatosis",
        "Primary sclerosing cholangitis (PSC)",
        "Progressive familial intrahepatic cholestasis",
        "Recurrent bacterial pertonitis",
        "Sclerosing cholangitis",
        "Secondary biliary cirrhosis",
        "Severe sustained jaundice",
        "End-stage hepatic disease is present or rapidly inevitable",
        "Thrombosis of major liver vessels",
        "Urea cycle deficiencies",
        "Variceal hemorrhage",
        "Veno-occlusive disease",
        "Wilson's disease",
        "Worsening nutritional status",
        "Type I Diabetes: BMI < or = 32",
        "Past total pancreatectomy for benign conditions",
        "Diabetic complications inc diab retinopathy, neuropathy, gastropathy, vasculopathy",
        "Type I Diabetes: Brittle control of blood sugar, fluctuations of high and low",
        "Type I Diabetes: C-Peptide level < or = 0.5",
        "Type I Diab: Creat clear >or = 40 mg/dl w calcineurin inhibitors & protein urea < 1gm",
        "Type I Diabetes: Evidence of poor glucose control",
        "Type I Diabetes: Insulin dependent",
        "Type I Diabetes: Recurring severe ketoacidosis",
        "Type I Diabetes: Secondary diabetic complications",
        "Type I Diabetes: Stable kidney transplant function",
        "Type II Diabetes: BMI < or = 32",
        "Type II Diabetes: C-Peptide level < or = 0.5",
        "Type II Diabetes: Creatinine clearance > or = 60 mg/dl and protein urea < 1 gm",
        "Type II Diabetes: Evidence of poor glucose control",
        "Type II Diabetes: History of insulin dependency with severe complications",
        "Type II Diabetes: Insulin dependent",
        "Type II Diabetes: Intensive management by endocrinology for at least 12 months"
      ]
    }
  ]
}
